Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Cheryl London"'
Publikováno v:
BMC Veterinary Research, Vol 17, Iss 1, Pp 1-8 (2021)
Abstract While a necessary step toward enhancing rigor and reproducibility of veterinary clinical trials conducted on the translational spectrum includes understanding the current state of the field, no broad assessment of existing veterinary clinica
Externí odkaz:
https://doaj.org/article/6b5f1e2cef0149c5ba4d23bbdcd12065
Autor:
Priya Londhe, Peter Y. Yu, Yuichi Ijiri, Katherine J. Ladner, Joelle M. Fenger, Cheryl London, Peter J. Houghton, Denis C. Guttridge
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
BackgroundMetabolic reprogramming has emerged as a cancer hallmark, and one of the well-known cancer-associated metabolic alterations is the increase in the rate of glycolysis. Recent reports have shown that both the classical and alternative signali
Externí odkaz:
https://doaj.org/article/454ae91c45e04e6990122e03d8a55e95
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0172822 (2017)
OBJECTIVES:To assess feasibility of the harmonic Osteovue blade (HOB) for use in the soft tissue approach for dogs undergoing hemilaminectomy and to compare outcomes between dogs undergoing HOB or traditional approach (TRAD). METHODS:A prospective ra
Externí odkaz:
https://doaj.org/article/1109fdd7a01f44d6bc5a582d8c8dd3da
Autor:
Maja L Arendt, Malin Melin, Noriko Tonomura, Michele Koltookian, Celine Courtay-Cahen, Netty Flindall, Joyce Bass, Kim Boerkamp, Katherine Megquir, Lisa Youell, Sue Murphy, Colleen McCarthy, Cheryl London, Gerard R Rutteman, Mike Starkey, Kerstin Lindblad-Toh
Publikováno v:
PLoS Genetics, Vol 11, Iss 11, p e1005647 (2015)
Canine mast cell tumours (CMCT) are one of the most common skin tumours in dogs with a major impact on canine health. Certain breeds have a higher risk of developing mast cell tumours, suggesting that underlying predisposing germ-line genetic factors
Externí odkaz:
https://doaj.org/article/895b2898a7834518bb77388c3398301a
Autor:
Peter J. Houghton, Xiaokui Mo, Laurence H. Baker, Cheryl London, Jiayuh Lin, Denis C. Guttridge, Linlin Xaio, Doris A. Phelps, Hemant K. Bid
The bromodomain and extra-terminal domain inhibitor JQ1 has marked antitumor activity against several hematologic malignancies as well as solid tumor models. Here, we investigated its activity in vitro and in vivo against models of childhood rhabdomy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eba441bdabcac029dcfc62a1a92da2d8
https://doi.org/10.1158/1535-7163.c.6538732.v1
https://doi.org/10.1158/1535-7163.c.6538732.v1
Autor:
Peter J. Houghton, Xiaokui Mo, Laurence H. Baker, Cheryl London, Jiayuh Lin, Denis C. Guttridge, Linlin Xaio, Doris A. Phelps, Hemant K. Bid
Supplemental Figure Legends; Supplemental Figure 1. JQ1 induces G1 accumulation without enhancing the sub-G1 population in sensitive sarcoma cell lines. Cells were exposed for 24 Hr to 500 nM JQ1; Supplemental Figure 2. Quantitation of immunoblots fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d95d0e38b8e93962710e99c685718a1
https://doi.org/10.1158/1535-7163.22507591.v1
https://doi.org/10.1158/1535-7163.22507591.v1
Autor:
Yves Pommier, James H. Doroshow, Jan H. Beumer, Julie Eiseman, Miguel Muzzio, Julianne L. Holleran, Joseph Tomaszewski, Heather Wilson-Robles, Nicole Northup, Kelvin Kow, Timothy Fan, Michael Kent, E.J. Ehrhart, Lisa Barber, Jeffrey N. Bryan, Michael Childress, David Vail, Erika Krick, William Kisseberth, Cheryl London, Kristen Weishaar, Sue Lana, Melissa Paoloni, Chand Khanna, Ralph E. Parchment, Robert J. Kinders, Jiuping Ji, Joseph M. Covey, Amy LeBlanc, Christina Mazcko, Jenna H. Burton
All supplementary files together
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6bc47299d9db5f59422b41191ade8c3
https://doi.org/10.1158/1078-0432.22469313
https://doi.org/10.1158/1078-0432.22469313
Autor:
Yves Pommier, James H. Doroshow, Jan H. Beumer, Julie Eiseman, Miguel Muzzio, Julianne L. Holleran, Joseph Tomaszewski, Heather Wilson-Robles, Nicole Northup, Kelvin Kow, Timothy Fan, Michael Kent, E.J. Ehrhart, Lisa Barber, Jeffrey N. Bryan, Michael Childress, David Vail, Erika Krick, William Kisseberth, Cheryl London, Kristen Weishaar, Sue Lana, Melissa Paoloni, Chand Khanna, Ralph E. Parchment, Robert J. Kinders, Jiuping Ji, Joseph M. Covey, Amy LeBlanc, Christina Mazcko, Jenna H. Burton
Purpose:Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used. Because of their limitations (chemical instability, drug efflux-mediated resistance, and diarrhea), nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36108e2ffff164835c28b3a1445044dc
https://doi.org/10.1158/1078-0432.c.6527208
https://doi.org/10.1158/1078-0432.c.6527208
Autor:
Cheryl London, Dan Regan, Lyndah Chow, Kristen Weishaar, Heather Gardner, Doug Thamm, Steven Dow
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Sarah E. Church, Cheryl London, Christine M. Toedebusch, Ben Sutton, Sarah Weigel, Erin Piazza
Publikováno v:
Cancer Research. 83:46-46
Background: Combination therapy to treat hematological and solid malignancies including chemotherapy, radiation, targeted and immunotherapy all hold huge potential for eliciting clinical responses. Informative pre-clinical testing of these approaches